IM Cannabis (NASDAQ:IMCC – Get Free Report) and Alpha Cognition (NASDAQ:ACOG – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares IM Cannabis and Alpha Cognition”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
| Alpha Cognition | $10.22 million | 18.75 | -$20.67 million | ($1.10) | -8.00 |
Profitability
This table compares IM Cannabis and Alpha Cognition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
Institutional & Insider Ownership
7.7% of IM Cannabis shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
IM Cannabis has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for IM Cannabis and Alpha Cognition, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 104.55%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than IM Cannabis.
Summary
Alpha Cognition beats IM Cannabis on 9 of the 14 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
